Calcium mobilization is one of the fastest and most sensitive ways to measure GPCR activation, but no single readout fits every question. This article walks through how calcium assays work, compares dye-based, aequorin, and genetically encoded detection approaches, and shows how to match the right cell model and assay format to your drug discovery goals.

An amylin receptor is a calcitonin receptor paired with a RAMP, and in a standard cell line the calcitonin side dominates, so the pharmacology reads as calcitonin, not amylin. Here is why that happens, how a low-expression approach fixes it, and what clean cAMP and β-arrestin readouts across AMY1, AMY2, and AMY3 open up for obesity and diabetes drug discovery.

Signaling bias is critical for drug discovery as it forms a selection criterion for agonism. Measuring and quantifying signaling bias reveals which candidates emphasize therapeutically beneficial pathways, and which may be falsely characterized as equivalent by single-pathway assays. Drug discovery programs that do not consider investigating for signaling bias often fail to fully understand the distinction and risk candidate molecules from advancing along the pipeline.

GPCRs are no longer simple on/off switches. Discover how biased signaling and functional assays are reshaping GPCR drug discovery.

Dr. GPCR and Eurofins DiscoverX announce a strategic partnership to accelerate GPCR drug discovery by expanding access to validated, industry-standard cell-based assay platforms supporting pharmacological characterization, screening, and regulatory-compliant development.